A Study Assessing KB707 for Cancer Treatment
Phase 1/2
240
about 3.8 years
18+
15 sites in CA, FL, IN +8
What this study is about
This trial is testing a new treatment called KB707 in people with advanced cancer. The goal is to see if KB707 is safe and helps fight the cancer. Participants will receive KB707, either alone or with other medications like Opdualag or Keytruda, depending on their specific situation.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive KB707
- 2.Take KEYTRUDA ®( Pembrolizumab)
- 3.Take Opdualag
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
immunotherapy (PD-1 inhibitor immunotherapy (pembrolizumab)), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Percentage of adverse events (AEs), Percentage of serious adverse events (SAEs)
Secondary: Maximum tolerated dose (MTD), Percentage of overall response rate (ORR)
Oncology